Atezolizumab has been approved as monotherapy for first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (either ≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells) and no EGFR alteration or ALK translocation. This evidence concerns the gene ALK and neoplasm.